PTC Therapeutics(US:PTCT)2026-01-12 17:00Revenue Projections - PTC Therapeutics, Inc. expects to report total unaudited net product and royalty revenue of approximately $823.4 million for the fiscal year ending December 31, 2025[6]. - The company anticipates total unaudited net product revenue of approximately $587.8 million for the same period[6]. - Unaudited net product revenue for Sephience™ (sepiapterin) is expected to be approximately $112.1 million[6]. - For the fiscal year ending December 31, 2026, the company projects total product revenues of $700 million to $800 million, excluding Evrysdi® (risdiplam) royalty revenue and collaboration revenue[7]. Expense Projections - GAAP R&D and SG&A expenses for 2026 are anticipated to be between $775 million and $815 million, while non-GAAP R&D and SG&A expenses are expected to be between $680 million and $720 million[7]. Upcoming Events - The company will provide an update on 2025 accomplishments and highlight 2026 milestones at the 44th Annual J.P. Morgan Healthcare Conference[8]. - The presentation will include preliminary 2025 unaudited financial results and 2026 financial guidance[8]. Financial Reporting - Non-GAAP financial measures are used by management to assess operational trends and provide transparency into the company's performance[10]. - The financial information for 2025 is preliminary and subject to completion of the year-end audit[12]. - The company does not undertake to update or revise forward-looking statements except as required by law[12].